

UCREST BERHAD

(Company No.: 420056-K)

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 NOV 2023**

	Current Quarter Ended 30-Nov-2023 RM'000	Comparative Quarter Ended 30-Nov-2022 RM'000	Cumulative Year To Date 30-Nov-2023 RM'000	Cumulative Year To Date 30-Nov-2022 RM'000
Income				
Revenue	4,128	1,339	6,120	2,394
Cost of sales	(2,958)	(1,219)	(4,203)	(2,137)
Gross Profit	<u>1,170</u>	<u>120</u>	<u>1,917</u>	<u>257</u>
Other income	2,018	49	3,890	140
Total Income	6,146	1,388	10,010	2,534
Expenses				
Selling and distribution	(1)	(2)	(13)	(5)
Administrative and general expenses	(1,238)	(704)	(2,200)	(1,232)
Profit / (Loss) from Operations (EBITA)	<u>1,949</u>	<u>(537)</u>	<u>3,594</u>	<u>(840)</u>
Amortisation of Intangible Assets	(657)	(657)	(1,314)	(1,314)
Depreciation	(43)	(45)	(87)	(90)
Profit / (Loss) Before Interest and Taxes (EBIT)	<u>1,249</u>	<u>(1,239)</u>	<u>2,193</u>	<u>(2,244)</u>
ESOS Expenses	-	(1,771)	-	(1,771)
Profit / (Loss) Before Interest and Taxes	<u>1,249</u>	<u>(3,010)</u>	<u>2,193</u>	<u>(4,015)</u>
Finance Cost	(4)	(33)	(8)	(63)
Profit / (Loss) before Tax	<u>1,245</u>	<u>(3,043)</u>	<u>2,185</u>	<u>(4,078)</u>
Profit / (Loss) before tax is stated after charging/(crediting):-				
Interest income	(174)	(35)	(248)	(61)
Reversal of impairment loss on trade receivables	(1,758)	-	(3,488)	-
ESOS expenses	-	1,771	-	1,771
Depreciation and amortisation	700	702	1,401	1,404
Foreign exchange (gain) / loss	(50)	96	(98)	49
Income tax expense	-	-	-	-
Profit / (Loss) for the period	<u>1,245</u>	<u>(3,043)</u>	<u>2,185</u>	<u>(4,078)</u>
Foreign currency translation	55	(81)	161	145
Total Comprehensive Profit / (Loss)	<u>1,300</u>	<u>(3,124)</u>	<u>2,346</u>	<u>(3,933)</u>
Attributable to :-				
Owners of the Company	1,245	(3,043)	2,185	(4,078)
Non-Controlling Interests	-	-	-	-
	<u>1,245</u>	<u>(3,043)</u>	<u>2,185</u>	<u>(4,078)</u>
Total comprehensive profit / (loss) attributable to:-				
Owners of the Company	1,300	(3,124)	2,346	(3,933)
Non-Controlling Interests	-	-	-	-
	<u>1,300</u>	<u>(3,124)</u>	<u>2,346</u>	<u>(3,933)</u>
Earnings / (Loss) per share - Basic (sen)	0.17	(0.49)	0.29	(0.66)
- Diluted (sen)	0.17	(0.48)	0.29	(0.63)

Note:

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the audited financial statements for the period ended 31 May 2023 and the accompanying explanatory notes attached to the interim financial statements.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 NOV 2023

	As At 30 Nov 2023 RM'000	As At 31 May 2023 RM'000
<u>ASSETS</u>		
Non-Current Assets		
Property, Plant and Equipment	30	38
Right-of-use Assets	243	321
Intangible Assets	3,653	4,967
Trade Receivables	11,712	15,857
Total Non-Current Assets	<u>15,638</u>	<u>21,183</u>
Current Assets		
Trade Receivables	14,216	6,533
Other Receivables	113	1,217
Tax Recoverable	290	719
Deposits, Cash and Bank Balances	22,434	17,633
Total Current Assets	<u>37,053</u>	<u>26,102</u>
Total Assets	<u>52,691</u>	<u>47,285</u>
<u>EQUITY AND LIABILITIES</u>		
Capital and Reserves		
Share Capital	56,754	52,079
Reserves	(17,268)	(19,614)
Total Equity	<u>39,486</u>	<u>32,465</u>
Current Liabilities		
Trade Payables	11,510	12,910
Other Payables	1,437	1,577
Leased Liabilities	258	333
Bank Overdraft	-	-
Total Current Liabilities	<u>13,205</u>	<u>14,820</u>
Total Liabilities	<u>13,205</u>	<u>14,820</u>
Total Equity and Liabilities	<u>52,691</u>	<u>47,285</u>
Net Assets Per Share Attributable to owners of the Company (Sen)	5	5

Note:

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the year ended 31 May 2023 and the accompanying explanatory notes attached to the interim financial statements.

UCREST BERHAD

(Company No.: 420056-K)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 Nov 2023**

	Share Capital RM'000	Foreign Currency translation Reserve RM'000	ESOS Reserve RM'000	Accumulated Loss RM'000	Equity Attributable to the Owners of the Company RM'000	Total Equity RM'000
<u>Quarter ended 30 Nov 2023</u>						
Balance as at 1 Jun 2023 (Audited), As previously stated	52,079	1,675	127	(21,416)	32,465	32,465
Issuance of shares pursuant to private placement	4,675	-	-	-	4,675	4,675
Share options granted under ESOS	-	-	-	-	-	-
Lapsed share options	-	-	-	-	-	-
Profit/(loss) for the period	-	161	-	2,185	2,346	2,346
Comprehensive profit/(loss) for the period	4,675	161	-	2,185	7,021	7,021
Balance as at 30 Nov 2023 (Unaudited)	56,754	1,836	127	(19,231)	39,486	39,486

Note:

The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 May 2023 and the accompanying notes attached to the interim financial statements.

**CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 Nov 2023**

	6 Months to date ended 30/11/2023 RM'000	12 Months to date ended 31/05/2023 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	2,185	101
Adjustments for:		
Amortisation of intangible assets	1,314	2,628
Depreciation of property, plant and equipment	8	22
Depreciation of right-of-use asset	79	157
Impairment loss on trade receivables	-	765
Reversal of impairment loss on receivables	(3,488)	(3,391)
ESOS expenses	-	1,771
Finance costs	8	99
Interest income	(248)	(163)
Unrealised gain on foreign exchange translation	(129)	(353)
Unrealised loss on foreign exchange translation	32	165
Operating (loss)/profit before changes in working capital	<u>(239)</u>	<u>1,801</u>
Changes in working capital:-		
Trade and other receivables	1,056	(10,679)
Trade and other payables	<u>(1,572)</u>	<u>4,558</u>
Cash used in operations	<u>(755)</u>	<u>(4,320)</u>
Interest received	248	(108)
Tax refund	476	-
Tax paid	<u>(47)</u>	<u>163</u>
Net cash generated from / (used in) operating activities	<u>(78)</u>	<u>(4,265)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment	-	(7)
Net cash used in investing activities	<u>-</u>	<u>(7)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceed from issuance of share capital		
- private placement	4,675	-
- pursuant to exercise of ESOS	-	4,396
Repayment of lease liability	(75)	(146)
Interest paid	(8)	(20)
Net cash generated from financing activities	<u>4,592</u>	<u>4,230</u>
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	4,514	(42)
CASH AND CASH EQUIVALENTS AT 01 JUNE	17,633	15,487
EFFECTS OF EXCHANGE RATE CHANGES	287	2,188
CASH AND CASH EQUIVALENTS AS AT END OF THE FINANCIAL PERIOD	<u>22,434</u>	<u>17,633</u>

Cash and cash equivalents

Cash and cash equivalents included in the statements of cash flows comprise the following statements of financial position amounts:

Deposits	16,778	12,158
Cash and bank balances	5,656	5,475
	<u>22,434</u>	<u>17,633</u>

Note:

The condensed consolidated cash flow statement should be read in conjunction with the audited financial statements for the year ended 31 May 2023 and the accompanying notes attached to the interim financial statements.

SELECTED EXPLANATORY NOTES

1. Accounting Policies and Methods Of Computation

The current quarter financial report ended 30 Nov 2023 is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market.

The report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 May 2023. The explanatory notes attached to the quarterly financial report provide an explanation on events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 May 2023.

The accounting policies and methods of computation adopted by the Group in the quarterly financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 May 2023.

2. Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the audited financial statements for the year ended 31 May 2023 was not qualified.

3. Segmental Reporting

Geographical information

	<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	30-Nov-23	30-Nov-22	30-Nov-23	30-Nov-22
	RM'000	RM'000	RM'000	RM'000
Malaysia	-	-	60	-
International	4,128	1,339	6,060	2,394
Group revenue	4,128	1,339	6,120	2,394

4. Unusual Items

During the quarter under review, there were no unusual items affecting assets, liabilities, equity, net income, or cash flows of the Group.

5. Changes In Estimates Of Amount Reported Previously Affecting Current Interim Period

There are no changes in estimates of amount reported that will have a material effect in the current interim period.

6. Seasonality or Cyclicity

The operations of the Group are not subject to any seasonality or cyclicity factors.

7. Dividends Paid Or Proposed

Dividends were neither paid nor proposed during the current interim period.

8. Valuation of Property, Plant and Equipment

The Group has not carried out any valuation on its property, plant & equipment.

9. Debts and Equity Securities

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities.

10. Change In The Composition of The Group

There has been no change in the composition of the group for the quarter review.

SELECTED EXPLANATORY NOTES

11. Discontinued Operation

There were no discontinued operations within the activities of the Group for the quarter under review.

12. Capital Commitments

There were no capital commitments for the purchase of any property, plant and equipment or any other expenses that were not accounted for in the financial statements of the quarter under review.

13. Changes In Contingent Liabilities & Assets

There are no material contingent liabilities as at the date of this report.

14. Subsequent Events

There were no material events subsequent to the end of the reporting quarter that have not been reflected in the quarter under review.

Additional Information As Per ACE Market Listing Requirement

15. Review Of Performance

During the current quarter under review, the Group recorded a net profit attributable to Owners of the Company of RM1.245 million.

16. Material Change In the Profit / (Loss) Before Taxation Compared To The Results of :-

	<u>Immediate Preceding Quarter</u>		<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	<u>30-Nov-23</u>	<u>31-Aug-23</u>	<u>30-Nov-23</u>	<u>30-Nov-22</u>	<u>30-Nov-23</u>	<u>30-Nov-22</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
P/(L)BITDA	1,949	1,645	1,949	(537)	3,594	(840)
Less : Amortisation of intangible assets	(657)	(657)	(657)	(657)	(1,314)	(1,314)
Less : Depreciation	(43)	(44)	(43)	(45)	(87)	(90)
Less : ESOS expenses	-	-	-	(1,771)	-	(1,771)
Less : Finance cost	(4)	(4)	(4)	(33)	(8)	(63)
Profit / (Loss) before tax	<u>1,245</u>	<u>940</u>	<u>1,245</u>	<u>(3,043)</u>	<u>2,185</u>	<u>(4,078)</u>

The Group recorded profit before tax of RM 1.245 million in the current quarter, and profit before tax of RM 0.940 million in the immediate preceding quarter.

17. Commentary Of Prospects

iMedic has achieved another milestone in the HealthierSG certification program, i.e. it has passed the uploading/downloading and the interface of National Electronic Health Record (NEHR) of Ministry of Health, Singapore. NEHR is the central depository of EHR of Singaporeans where all clinics/hospitals are required to upload whenever there is a new data. Doctors and patients will have access of the EHR from any platform. This will accelerate the adoption of iMedic in the market.

While developing the 3D printing business in the medical market, the Group is developing the 3D scanning technology to ensure input for 3D printing is precisely and accurately captured. This will greatly enhance the quality of the 3D printing technology expanding the market to the next level.

iMedic has jointly developed the Artificial Intelligence (AI) with Key ASIC in assisting ophthalmologist in the diagnosis of Diabetic Retinopathy (DR), Glaucoma, Aged Related Macular Degeneration (AMD), and other retina related diseases from images capture.

18. Profit Forecast

There was no profit forecast issued by the Group.

SELECTED EXPLANATORY NOTES

19. Taxation

There were no tax provision during the current interim period under review.

20. Unquoted Investments / Properties

There were no purchase or sales of unquoted investments or properties during the current interim period under review.

21. Purchase or Disposal of Quoted Securities

There were no purchase or disposal of quoted securities during the current interim period under review.

22. Status of Corporate Proposal

The Company had at the Annual General Meeting held on 25 November 2022 obtained the shareholders' approval for a private placement exercise to issue up to 70,481,900 new ordinary shares in the Company representing not more than ten percent (10%) of the issued share capital of the company ("Private Placement").

Bursa Securities had, vide its letter dated 25 May 2023, approved the listing and quotation of up to 70,481,900 Placement Shares to be issued pursuant to the Private Placement.

As at the date of this report, 50,000,000 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the ACE Market of Bursa Malaysia Securities Berhad.

Bursa Malaysia Securities Berhad had, vide its letter dated 20 November 2023, granted the Company approval for an extension of time of six months from 25 November 2023 to 24 May 2024 to complete the Proposed Private Placement.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Working capital	6,213	4,570	1,643
Expenses for the proposed private placement	130	105	25

23. Group Borrowings and Debt Securities

There were no borrowings and debts securities for the financial quarter under review.

24. Off Balance Sheet Financial Instruments

There were no off balance sheet financial instruments as at the date of this report.

25. Material Litigation

There were no Material Litigation for the financial quarter under review.

SELECTED EXPLANATORY NOTES

26. Realised and Unrealised Profits/Losses

On 25 March 2010, Bursa Securities issued a directive to all listed issuers pursuant to Rules 2.07 and 2.23 of Bursa Securities ACE Market Listing Requirements. The directive requires all listed issuers to disclose the breakdown of the unappropriated profits or accumulated losses as at the end of the reporting period, into realised and unrealised profits and losses.

On 20 December 2010, Bursa Securities further issued guidance on the disclose and the format period.

The breakdown of accumulated profit / (losses) of the Group as at the reporting date, into realised and unrealised losses, pursuant to the directive, is as follows:

	Group	
	<u>Unaudited</u> 30/11/2023 RM'000	<u>Audited</u> 31/05/2023 RM'000
Total accumulated profit / (losses) of UCrest Berhad and it's subsidiaries:		
- Realised	(19,133)	(21,251)
- Unrealised - in respect of other items of income and expense	(98)	(165)
Total Group accumulated profit as per consolidated accounts	<u>(19,231)</u>	<u>(21,416)</u>

The determination of realised and unrealised losses is based on the Guidance of Special Matter No.1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements, issued by the Malaysian Institute of Accountants on 20 December 2010.

The disclosure of realised and unrealised losses above is solely for complying with the disclosure requirements stipulated in the directive of Bursa Malaysia and should not be applied for any other purposes.

27. Dividends Payable

The Board of Directors does not recommend any interim dividends for the current quarter ended 30 Nov 2023.

28. Earnings / (Loss) Per Share

(a) Basic

The basic earnings / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<u>Individual quarter ended</u>		<u>Cumulative YTD</u>	
	<u>Unaudited</u> 30-Nov-23	<u>Unaudited</u> 30-Nov-22	<u>Unaudited</u> 30-Nov-23	<u>Audited</u> 30-Nov-22
Net profit / (loss) attributable to owners of the company (RM'000)	1,245	(3,043)	2,185	(4,078)
Weighted average number of ordinary shares in issue ('000)	741,877	621,877	741,877	621,877
Basic earnings / (loss) per share (sen)	<u>0.17</u>	<u>(0.49)</u>	<u>0.29</u>	<u>(0.66)</u>

(b) Diluted

The diluted earning / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<u>Individual quarter ended</u>		<u>Cumulative YTD</u>	
	<u>Unaudited</u> 30-Nov-23	<u>Unaudited</u> 30-Nov-22	<u>Unaudited</u> 30-Nov-23	<u>Audited</u> 30-Nov-22
Net profit / (loss) attributable to owners of the company (RM'000)	1,245	(3,043)	2,185	(4,078)
Dilutive shares on option outstanding ('000)	742,825	632,949	742,781	642,630
Diluted earnings / (loss) per share (sen)	<u>0.17</u>	<u>(0.48)</u>	<u>0.29</u>	<u>(0.63)</u>